

CSO Thomas Jonassen Resomelagon - AP-1189: Program Overview and Updates


SynAct Pharma – Pipeline overview


Asset	Indication	Pre-clinical	Phase I	Phase Ila	Phase IIb	Phase III
	Rheumatoid Arthritis Severe treatment-naïve with MTX					
	Rheumatoid Arthritis DMARD-IR				<u>></u> >	
AP1189	Nephrotic syndrome (iMN)				>	
	Virus- Induced Respiratory Insufficiency				,	
TXP-11	Prevention of organ failures in complicated surgery					
Small Molecules and Peptides	Autoimmune and inflammatory conditions					
	Completed	>	Ongoing	,	Resolve Part E	



Resomelagon (AP1189): Once-Daily Oral Selective MC1R and MC3R Agonist in Phase 2 clinical Development for Autoimmune and Inflammatory Diseases

SynAct is developing selective melanocortin agonists with both anti-inflammatory and pro-inflammation resolution activity






- Selective stimulation of melanocortin receptors 1 and 3 (MC1R and MC3R) present on immune active cells promotes direct immunomodulatory effects
- Neither AP1189 nor TXP-11 activates MC2R, present in the adrenal glands, which causes the release of cortisol when stimulated and results in steroid side effects and tolerability issues
- AP1189 exbibits anti-inflammatory activity via MC1R and MC3R stimulation on targets cells – such as lowering the release of proinflammatory cytokines
- AP1189 promotes pro-resolution pathways following stimulation of MC1R and MC3R on targets cells – such as increasing efferocytosis in macrophages

Lead Program AP1189 – A once-daily oral selective melanocortin agonist


- AP1189 selectively stimulates MC1R and MC3R present on white cells including neutrophils and macrophages
- Reduction but not suppression of cell infiltration and release of pro-inflammatory pathways
- Stimulation of pro-resolving pathways including the ability to stimulate the macrophages' ability to efferocytosis
- As AP1189 is also a biased agonist, the compound will not induce melanogenesis following in vitro stimulation of MC1R





AP1189 promotes inflammatory resolutionAP1189


Melanin production following stimulation of MC1r¹




1. Montero-Melendez et al: J Immunol. 194:3381-8, 2015

AP1189 was well tolerated in Phase 1 and Phase 2a studies with pharmacokinetic profile supporting once daily dosing

- Initial clinical development, Phase 1 and Phase 2a, performed with suspension for once daily oral administration was overall well tolerated, no signs of immunosuppression or dose limiting Adverse Events
- Novel immediate release tablet with excellent plasma profile developed and is being dosed in 3 ongoing Phase 2 studies



1. AP1189-CS001 study MAD study



2. AP1189-CS004 bioequivalence study in male volunteers



Resomelagon (AP-1189)- RA – program




The **BEGIN Study**:


A double-blind, multi-centre, two-part, randomized, placebo-controlled study of the safety, tolerability, and efficacy of 4 weeks of treatment with AP1189 in early rheumatoid arthritis patients with active joint disease

Completed Q4 2021

BEGIN: P2a POC 4-week study of AP1189 + MTX in highly active early RA


Study Population	Primary safety endpoint	Primary efficacy endpoint
Adult patients (aged 18 to 85 years) with severe RA defined as CDAI >22, who are about to begin up-titration with MTX	Safety of AP1189 vs placebo (AEs and SAEs)	 Mean change in CDAI or % of patients improving from severe (CDAI >22) to at least moderate (CDAI ≤22)






AP1189 demonstrated significant treatment effects in patients with severe treatment-naïve RA in the 4-week BEGIN P2a clinical trial

Phase 2a study in treatment naive RA patients with high disease activity (CDAI >22 at randomization) in combination with MTX with 4 weeks treatment



Mean improvement in CDAI above the minimally important clinical difference (MCID)⁺ Robust 1-Month ACR20/50/70 response rates for 100mg AP1189

Meaningful improvements were also seen in DAS28 (CRP) and FACIT-Fatigue Scores



4-Week daily AP1189 dosing was safe and well tolerated in the BEGIN study

Adverse Events ¹					
Group (p)	Placebo + MTX (34)	AP118	Total		
Group (n)		50 mg (35)	100 mg (36)	(105)	
SAEs n	0	0	0	0	
AEs n	34	65	53	152	
Mild/Mod/Severe	28/4/2	45/20/0	43/10/0	116/34/2	
% Mild	82%	69%	81%	76%	
Pts with ≥ 1 AE n (%)	17 (50)	20 (57)	20 (56)	57 (54)	
Discontinuation n (%)	1 ² (3)	0 (0)	1 ³ (3)	2 (2)	
AEs >10% of Pts, n					
Nausea ⁴	7	5	7	19	
ALT increase ⁵	3	6	0	9	
Headache ⁴	0	2	5	7	

(1) All study AEs; As per protocol safety assessments were conducted at level of all AEs not only treatment-emergent AEs

(2) Baseline ALT>3x upper normal level; patient discontinued from study when levels were read

(3) Onset of herpes zoster; Investigator decided to DC MTX which necessitated study discontinuation

(4) Headache and nausea were transient and occurred more frequently early in dosing period

(5) Laboratory value AEs determined by investigator; 8/10 ALT increases were mild and 3 occurred outside of dosing period



The EXPAND study

A double-blind, multi-center, randomized, placebo-controlled study of the safety and efficacy of 12 weeks extended treatment with Resomelagon (AP1189) in early rheumatoid arthritis (RA) patients naïve to DMARD treatment –

Recruitment completed in April 2023

EXPAND STUDY P2b study in previous treatment naive RA patients. Recruitment completed in April 2023 -

Patient Population: Previous treatment naïve, eligible for Resomelagon (AP1189) 100* mg, combination with MTX initiation of DMARD treatment (MTX) CDAL>22 at baseline – min of 6 swollen Placebo, combination with MTX and tender joints Glucocorticoids only allowed as rescue 12 Weeks dosing medicine **Key Study Parameters Dosing and Duration** 12 weeks of once-daily dosing of solid tablet AP1189 or placebo- conducted at site in Eastern Europe- Successful completion of recruitment ahead of schedule **Study Size and Sites** Designed to recruit 60 patients per group – actual number randomized is 127 **Primary Endpoints** ACR20 response rate at 12 weeks as compared to placebo Secondary Endpoints CDAI score; DAS28 score; FACIT-Fatigue; HAQ/RAQol **MRI-** SubStudy Evaluation of Synovial inflammation using Dynamic Contrast Enhanced MRI Quantification (DEMRIQ) *: Free base – correspond to 125 mg acetate salt used in the BEGIN study PHARMA SYNACT INFLAMMATION RESOLUTION



The **RESOLVE** study

A two-part, randomized, double-blind, multi-center, placebo-controlled study of the dose-range, safety and efficacy of 4 and 12 weeks of treatment with AP1189 in adult rheumatoid arthritis (RA) patients with an inadequate response to Methotrexate (MTX) alone

Conducted under and US-IND Recruitment to part A ongoing

AP1189- Adaptive P2 trial design in DMARD-IR patients

Currently recruiting in US and Europe under an US- IND- Data on part A in H2 2023

Part A – 4 weeks dosing

3 dose levels of Resomelagon (AP1189) cont. MTX

Placebo, cont. MTX

Part B – 12 weeks dosing

Up to 3 dose levels of Resomelagon (AP1189), cont. MTX

Placebo, cont. MTX

	Key Study Parameters	
Patient Population:	Dosing	 Once-daily dosing of solid tablet AP1189 or placebo
>3 mo MTX treatment	Study Size and Sites	 Part A: 30 pts per group Part B: 75 patients per group
 Documented incomplete response or loss of response 	Primary Efficacy Endpoints	 ACR20 response rate at 4 Weeks (part A) and 12 weeks as compared to placebo
 Min of 6 swollen and 6 tender joints and/or increased CRP 	Secondary Endpoints	 CDAI score; DAS28 score; FACIT-Fatigue; HAQ/RAQol
joints and/or increased enr	MRI- substudy (part B only)	 Evaluation of Synovial inflammation and potential effects on joint destruction using Dynamic Contrast Enhanced MRI Quantification (DEMRIQ)



Resomelagon (AP1189) Nephrology program -

Exploratory Phase 2 study conducted at Nephrology sites in the Nordic Countries

An exploratory, randomized, double-blind, multicenter, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and efficacy of AP1189 daily doses versus placebo administered for 12 weeks as an add-on to patients, in ACE inhibitor or angiotensin II receptor blocker treatment, with idiopathic membranous nephropathy and severe proteinuria

AP1189 is effective in pre-clinical nephritis models


Vehicle (n=12)

AP1189 (n=12)


Membranous nephropathy rat model (passive Heymann Nephritis)

Albumin excretion rate


Creatinine Clearance (ml/min/g KW)









AP1189 showed no effect on creatinine clearance where albumin excretion decreased significantly



AP1189 vs ACTH in a model of Nephrotic Syndrome






AP1189 preserved creatinine clearance and dose-dependently reduced the fractional albumin excretion relative to ACTH

*p<0.05 vs. Day 14; † p<0.05 vs. vehicle; ‡ p<0.01 vs. ACTH; data from PCT/EP2019/066578. Model adapted from Lindskog et al, J Am Soc Nephrol. 2010; 21:1290-1298

Ongoing study: CS-003 study – 12 weeks explorative Phase 2a trial in idiopathic membranous nephropathy (iMN) with severe proteinuria



- Dosing is ongoing following approval of major amendment changing from suspension to tablet and dosing extended to 12 weeks.
- The trial resumed in H2 2022 with topline data expected late in 2023



Thank you